- Charles River Laboratories press release ( NYSE: CRL ): Q2 Non-GAAP EPS of $2.77 beats by $0.03 .
- Revenue of $973.1M (+6.4% Y/Y) misses by $22.02M .
- The company’s updated guidance for revenue growth, earnings per share, and cash flow is as follows : Revenue growth of 9.0% – 11.0%; Revenue growth, organic of 10.0% – 12.0% vs. estimated growth of 13.12% Y/Y; GAAP EPS of $7.90 – $8.15; Non-GAAP EPS of $10.70 – $10.95 vs. consensus of $11.53; Cash flow from operating activities of ~$700 million; Capital expenditures of ~$340 million and Free cash flow of ~$360 million.
For further details see:
Charles River Laboratories reports mixed Q2 earnings; narrows FY22 guidance